Skip to main content
. 2020 Aug 28;11:4320. doi: 10.1038/s41467-020-18104-5

Fig. 7. Benzbromarone inhibits polycystic kidney disease in a mouse model for ADPKD.

Fig. 7

a Representative images of kidneys from non-induced (Pkd1+/+) and induced (Pkd1−/−) mice (n = 5 animals each), untreated (daily i.p. injection of corn oil) or treated with benzbromarone in corn oil (BBR, 1 mg/kg/day, i.p.) for 30 days. Scale bars: 1000 µm. b Cystic index (%) 8 weeks after induction of Pkd1+/+ and Pkd1−/− mice, untreated or treated with benzbromarone. Cyst growth was induced in Pkd1−/− mice (#P < 0.0001), but was inhibited by benzbromarone (§P < 0.0001) (n = 10 kidneys analyzed from n = 5 animals each). c Time course of body weight for untreated and benzbromarone-treated Pkd1+/+ and Pkd1−/− mice. Body weight gain was enhanced in Pkd1−/− mice (#P < 0.05), but was inhibited by benzbromarone (§P < 0.05) (n = 8 kidneys analyzed from n = 5 animals each). d, e Proliferating cells identified in Pkd1+/+ and Pkd1−/− kidneys by the proliferation marker ki-67 (red). Proliferation was upregulated in Pkd1−/− kidneys (#P < 0.0001), but was inhibited by benzbromarone (§P < 0.0001) (25 independent images from n = 5 animals each). Scale bar 50 µm. Number of ki-67 positive cells was normalized to the tissue area. Mean and error bars indicating ±SEM. #§One-way ANOVA and Tukey’s post-hoc test comparing Pkd1+/+ with Pkd1−/− and Pkd1−/− with Pkd1−/−/T16a−/−, respectively. Source data are provided as a Source Data file.